New insights into mechanisms of breast cancer development and resistance to therapy

January 9, 2017
Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia

Why does breast cancer develop and how come certain patients are resistant to established therapies? Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified the tumor suppressor LATS as a key player in the development and treatment of breast cancer. The journal Nature has published the results today.

All breast cancers are not created equal. In up to 70 percent of all breast cancers, the tumor has receptors for the hormone estrogen. Today, these estrogen-receptor-positive cancers can be treated relatively well. Because these tumors need estrogen for their growth, the receptor is the target of a number of drugs that interfere with estrogen expression, bind to the receptor or speed up its degeneration.

However, around a third of all patients does not react to therapy or develops resistance. So far it has not been possible to accurately predict who will respond to this therapy because the underlying molecular mechanisms are not yet understood entirely.

In a comprehensive molecular study, a group of scientists led by Prof. Mohamed Bentires-Alj from the Department of Biomedicine at the University and the University Hospital of Basel has now identified an important player in this process named LATS. They were able to show how this enzyme, in cooperation with other proteins, influences the development and treatment of breast cancer.

Tumor suppressor LATS decides cell fate

The researchers focused on cancer-inhibiting genes that prevent normal cells from becoming cancerous. In particular, they studied the tumor suppressors LATS1 and LATS2. Once LATS is deleted, the processes in the breast tissue change.

Without LATS, the number of so-called luminal precursor cells in the epithelial tissue of breast glands increases. These are the cells of origin of most types of in humans. "LATS balances cell fate in the breast tissue. In its absence the equilibrium shifts and more cells that can give rise to tumors develop", explains Bentires-Alj.

Resistance to degradation

In healthy breast tissue, LATS brings together the with the protein degradation machinery. Without LATS the receptor can no longer be properly degraded, which has consequences for cancer therapy. "We were able to show that cancer cells without LATS no longer respond to Fluvestrant, an estrogen-receptor antagonist that promotes its degradation. They were resistant", says Bentires-Alj.

The removal of LATS also stabilized the proteins YAP and TAZ, which are upregulated in many cancers and boost cell proliferation. "Thanks to our newly gained insights into the in healthy , we now also better understand how cells of origin of cancer expand and why certain tumors are resistant to therapy", summarizes the Basel scientists Bentires-Alj.

Explore further: Prevalence of estrogen receptor mutations in patients with metastatic breast cancer

More information: Adrian Britschgi et al, The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα, Nature (2017). DOI: 10.1038/nature20829

Related Stories

Prevalence of estrogen receptor mutations in patients with metastatic breast cancer

August 11, 2016
A new study published online by JAMA Oncology examines the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.

Researchers explain breast cancer resistance to hormone therapy and point to potential new therapies

October 4, 2016
Despite the overall success of hormone therapy, breast cancer tumors in patients with metastatic disease often fail to respond. One new mechanism that can explain resistance to hormone therapy in breast cancer involves two ...

A new tumor suppressor gene for breast cancer in mice

September 13, 2016
Researchers at Tokyo Institute of Technology revealed a role for an X-linked protein kinase Nrk in terminating the proliferation of mammary epithelial cells during pregnancy and thereby preventing breast tumorigenesis in ...

Breast cancer: An improved animal model opens up new treatments

March 3, 2016
EPFL scientists have developed an animal model for breast cancer that faithfully captures the disease. Tested on human breast tissue, this the most clinically realistic model of breast cancer to date.

Tamoxifen resistance linked to high estrogen levels in utero

September 8, 2016
An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor positive breast cancers may originate from in utero exposure to endocrine disrupting chemicals. The study provides a new path forward ...

Recommended for you

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.